GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tissue Regenix Group PLC (LSE:TRX) » Definitions » Gross Profit

Tissue Regenix Group (LSE:TRX) Gross Profit : £11.11 Mil (TTM As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Tissue Regenix Group Gross Profit?

Tissue Regenix Group's gross profit for the six months ended in Dec. 2023 was £5.62 Mil. Tissue Regenix Group's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was £11.11 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Tissue Regenix Group's gross profit for the six months ended in Dec. 2023 was £5.62 Mil. Tissue Regenix Group's Revenue for the six months ended in Dec. 2023 was £12.16 Mil. Therefore, Tissue Regenix Group's Gross Margin % for the quarter that ended in Dec. 2023 was 46.23%.

Tissue Regenix Group had a gross margin of 46.23% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Tissue Regenix Group was 81.06%. The lowest was 42.93%. And the median was 47.61%.

Warning Sign:

Tissue Regenix Group PLC gross margin has been in long-term decline. The average rate of decline per year is -1.2%.


Tissue Regenix Group Gross Profit Historical Data

The historical data trend for Tissue Regenix Group's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tissue Regenix Group Gross Profit Chart

Tissue Regenix Group Annual Data
Trend Jan14 Jan15 Jan16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.02 5.63 6.37 9.24 11.09

Tissue Regenix Group Semi-Annual Data
Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.13 4.40 4.79 5.48 5.62

Competitive Comparison of Tissue Regenix Group's Gross Profit

For the Biotechnology subindustry, Tissue Regenix Group's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tissue Regenix Group's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Gross Profit distribution charts can be found below:

* The bar in red indicates where Tissue Regenix Group's Gross Profit falls into.



Tissue Regenix Group Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Tissue Regenix Group's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=23.299 - 12.207
=11.09

Tissue Regenix Group's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=12.162 - 6.54
=5.62

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £11.11 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Tissue Regenix Group's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=5.62 / 12.162
=46.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Tissue Regenix Group  (LSE:TRX) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Tissue Regenix Group had a gross margin of 46.23% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Tissue Regenix Group Gross Profit Related Terms

Thank you for viewing the detailed overview of Tissue Regenix Group's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Tissue Regenix Group (LSE:TRX) Business Description

Traded in Other Exchanges
Address
Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.